Emergent wins FDA nod for anthrax drug Anthrasil

The FDA has given its blessing to Emergent BioSolutions' intravenous immune globulin drug Anthrasil as a treatment in combination with appropriate antibacterials for inhalational anthrax, which is caused by breathing in the spores of the bacterium Bacillus anthracis.

The FDA has given its blessing to Emergent BioSolutions' intravenous immune globulin drug Anthrasil as a treatment in combination with appropriate antibacterials for inhalational anthrax, which is caused by breathing in the spores of the bacterium Bacillus anthracis.

When inhaled, the anthrax bacteria replicate in the body and produce toxins that can cause massive and irreversible tissue injury...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category